22
22Z.F Zealand Pharma A/S
- Market cap
- EUR 2.19B
- P/E
- 6.4x
- P/B
- 0.90x
- ROE
- 39.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 22Z.F undervalued?
Graham number22Z.F trades 49.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zealand Pharma A/S fundamental analysis
No fundamental analysis for Zealand Pharma A/S yet.
Zealand Pharma A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas sys…
Full company profileZealand Pharma A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zealand Pharma A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 235M | 140M | 38.0M | 41.3M | 353M | 293M | 104M | 343M | 62.7M | 9.21B | 9.05B |
| Gross Profit | 203M | 125M | -142M | 40.9M | 263M | 174M | 104M | 324M | 54.8M | 9.21B | 9.05B |
| Operating Income | -116M | -246M | -658M | -588M | -829M | -1.05B | -817M | -577M | -1.27B | 7.11B | 6.64B |
| EBITDA | - | -254M | 645M | -560M | -794M | -983M | -798M | -658M | -1.02B | 7.06B | 7.29B |
| Net Income | -154M | -272M | 581M | -572M | -847M | -1.02B | -1.20B | -704M | -1.08B | 6.46B | 7.05B |
| EPS | - | -8.87 | 19 | -16 | -21 | -24 | -23 | -12 | -15 | 91 | 102 |
| Balance Sheet | |||||||||||
| Total Assets | 695M | 737M | 1.23B | 1.60B | 1.92B | 2.07B | 1.54B | 1.98B | 9.51B | 15.9B | 19.8B |
| Total Liabilities | 416M | 209M | 114M | 357M | 748M | 1.14B | 724M | 387M | 889M | 1.12B | 1.76B |
| Shareholders' Equity | 278M | 528M | 1.12B | 1.24B | 1.18B | 928M | 816M | 1.59B | 8.62B | 14.8B | 18.0B |
| Cash & Short-term Investments | 323M | 589M | 861M | 1.08B | 861M | 1.13B | 1.07B | 449M | 480M | 4.58B | 4.04B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 40.9M | -279M | -461M | -409M | -689M | -1.21B | -942M | -426M | -931M | 6.53B | -532M |
| Capital Expenditure | 2.60M | 7.23M | 4.04M | 21.0M | 25.0M | 22.1M | 11.7M | 23.7M | 13.1M | 69.1M | 50.0M |
| Free Cash Flow | - | -286M | -464M | -433M | -714M | -1.23B | -954M | -449M | -944M | 6.46B | -582M |
| Ratios | |||||||||||
| ROE | -55.3% | -51.5% | 52.1% | -46.0% | -71.9% | -109.7% | -147.3% | -44.2% | -12.5% | 43.5% | 39.1% |
| ROA | -22.2% | -36.9% | 47.3% | -35.7% | -44.0% | -49.2% | -78.1% | -35.5% | -11.3% | 40.5% | 35.7% |
| Net Profit Margin | -65.6% | -194.8% | 1,530.6% | -1,382.8% | -239.7% | -348.0% | -1,156.1% | -205.3% | -1,720.9% | 70.0% | 77.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zealand Pharma A/S dividends
Zealand Pharma A/S has not paid dividends in the last 9 fiscal years.
Who owns Zealand Pharma A/S
- Insiders 0.53%
- Institutions 38.53%
- Public & others 60.94%
- Shares outstanding 66.3M
- Free float 59.4M
Zealand Pharma A/S company profile
- Company name
- Zealand Pharma A/S
- Ticker
- 22Z.F
- ISIN
- DK0060257814
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 578
- Fiscal year end
- December
- Address
- Sydmarken 11, Søborg, Denmark, 2860
- Phone
- 45 88 77 36 00
- Website
- zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Zealand Pharma A/S management
10- Mr. Adam Sinding Steensberg M.D.President & CEO · born 1974
- Ms. Henriette WennickeEVP & CFO · born 1983
- Mr. Ivan Mourits MollerExecutive VP & COO
- Mr. Utpal SinghExecutive VP & Chief Scientific Officer · born 1974
- Mr. Eric RojasVP & Head of Investor Relations
- Mr. Ravinder Singh ChahilEVP & General Counsel · born 1968
- Ms. Christina Sonnenborg BredalExecutive VP & Chief People Officer · born 1985
- Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular Pharmacology
- Dr. David M. Kendall M.D.Executive VP, Chief Medical Officer & Head of R&D · born 1961
- Mr. Eric CoxExecutive VP & Chief Commercial Officer · born 1967